{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:48:02Z","timestamp":1786981682216,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"msd greece"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11136-021-03044-4","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T01:02:38Z","timestamp":1638061358000},"page":"1385-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the \u2018GO-UP\u2019 study"],"prefix":"10.1007","volume":"31","author":[{"given":"Panagiotis","family":"Athanassiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kotrotsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kallitsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Garyfallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Vosvotekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Livieratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Petrikkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-7416","authenticated-orcid":false,"given":"Gkikas","family":"Katsifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,28]]},"reference":[{"issue":"4","key":"3044_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A., & Cats, A. (1984). Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism, 27(4), 361\u2013368. https:\/\/doi.org\/10.1002\/art.1780270401","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"3044_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M., van der Heijde, D., Landew\u00e9, R., Listing, J., Akkoc, N., Brandt, J., Braun, J., Chou, C. T., Collantes-Estevez, E., Dougados, M., Huang, F., Gu, J., Khan, M. A., Kirazli, Y., Maksymowych, W. P., Mielants, H., S\u00f8rensen, I. J., Ozgocmen, S., Roussou, E., \u2026 Sieper, J. (2009). The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Annals of the Rheumatic Diseases, 68(6), 777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Annals of the Rheumatic Diseases"},{"key":"3044_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key079","author":"J Braun","year":"2018","unstructured":"Braun, J. (2018). Axial spondyloarthritis including ankylosing spondylitis. Rheumatology (Oxford, England). https:\/\/doi.org\/10.1093\/rheumatology\/key079","journal-title":"Rheumatology (Oxford, England)"},{"issue":"9","key":"3044_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk, C., van Onna, M., Boonen, A., & van Tubergen, A. (2016). Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care & Research, 68(9), 1320\u20131331. https:\/\/doi.org\/10.1002\/acr.22831","journal-title":"Arthritis Care & Research"},{"issue":"1","key":"3044_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/03009740600904243","volume":"36","author":"R De Angelis","year":"2007","unstructured":"De Angelis, R., Salaffi, F., & Grassi, W. (2007). Prevalence of spondyloarthropathies in an Italian population sample: A regional community-based study. Scandinavian Journal of Rheumatology, 36(1), 14\u201321. https:\/\/doi.org\/10.1080\/03009740600904243","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"5","key":"3044_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu, T., & Gossec, L. (2018). Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 14(5), 405\u2013417. https:\/\/doi.org\/10.1080\/1744666X.2018.1468252","journal-title":"Expert Review of Clinical Immunology"},{"issue":"7","key":"3044_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand, V., & Singh, J. A. (2017). Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 23(7), 383\u2013391. https:\/\/doi.org\/10.1097\/RHU.0000000000000589","journal-title":"Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases"},{"issue":"4","key":"3044_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582","volume":"10","author":"B Michelsen","year":"2015","unstructured":"Michelsen, B., Fiane, R., Diamantopoulos, A. P., Soldal, D. M., Hansen, I. J., Sokka, T., Kavanaugh, A., & Haugeberg, G. (2015). A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One, 10(4), e0123582. https:\/\/doi.org\/10.1371\/journal.pone.0123582","journal-title":"PLoS One"},{"issue":"12","key":"3044_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted, J. A., Thavaneswaran, A., Chandran, V., Eder, L., Rosen, C. F., Cook, R. J., & Gladman, D. D. (2011). Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research, 63(12), 1729\u20131735. https:\/\/doi.org\/10.1002\/acr.20627","journal-title":"Arthritis Care & Research"},{"issue":"7","key":"3044_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10067-011-1692-7","volume":"30","author":"M Khraishi","year":"2011","unstructured":"Khraishi, M., MacDonald, D., Rampakakis, E., Vaillancourt, J., & Sampalis, J. S. (2011). Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clinical Rheumatology, 30(7), 877\u2013885. https:\/\/doi.org\/10.1007\/s10067-011-1692-7","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"3044_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-019-00172-9","volume":"6","author":"PJ Mease","year":"2019","unstructured":"Mease, P. J., Liu, M., Rebello, S., Kang, H., Yi, E., Park, Y., & Greenberg, J. D. (2019). Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corrona registries. Rheumatology and Therapy, 6(4), 529\u2013542. https:\/\/doi.org\/10.1007\/s40744-019-00172-9","journal-title":"Rheumatology and Therapy"},{"issue":"3","key":"3044_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.berh.2018.09.002","volume":"32","author":"A Molt\u00f3","year":"2018","unstructured":"Molt\u00f3, A., & Dougados, M. (2018). Comorbidities in spondyloarthritis including psoriatic arthritis. Best practice & research. Clinical Rheumatology, 32(3), 390\u2013400. https:\/\/doi.org\/10.1016\/j.berh.2018.09.002","journal-title":"Clinical Rheumatology"},{"issue":"10","key":"3044_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ncprheum0297","volume":"2","author":"A Boonen","year":"2006","unstructured":"Boonen, A. (2006). A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nature Clinical Practice. Rheumatology, 2(10), 546\u2013553. https:\/\/doi.org\/10.1038\/ncprheum0297","journal-title":"Nature Clinical Practice. Rheumatology"},{"issue":"1","key":"3044_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00296-018-4180-4","volume":"39","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger, K., Burmester, G. R., Wassenberg, S., Bohl-B\u00fchler, M., & Thomas, M. H. (2019). Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Non-interventional study GO-NICE in Germany. Rheumatology International, 39(1), 131\u2013140. https:\/\/doi.org\/10.1007\/s00296-018-4180-4","journal-title":"Rheumatology International"},{"issue":"1","key":"3044_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S., Sch\u00f6ls, M., Braun, J., Dougados, M., FitzGerald, O., Gladman, D. D., Kavanaugh, A., Landew\u00e9, R., Mease, P., Sieper, J., Stamm, T., Wit, M., Aletaha, D., Baraliakos, X., Betteridge, N., Bosch, F., Coates, L. C., Emery, P., Gensler, L. S., \u2026 van der Heijde, D. (2018). Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77(1), 3\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"3044_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landew\u00e9, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Ca\u00f1ete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., \u2026 van der Heijde, D. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75(3), 499\u2013510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"3044_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40744-017-0066-2","volume":"4","author":"M Garrido-Cumbrera","year":"2017","unstructured":"Garrido-Cumbrera, M., Hillmann, O., Mahapatra, R., Trigos, D., Zajc, P., Weiss, L., Bostynets, G., Gossec, L., & Coates, L. C. (2017). Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. Rheumatology and Therapy, 4(2), 219\u2013231. https:\/\/doi.org\/10.1007\/s40744-017-0066-2","journal-title":"Rheumatology and Therapy"},{"issue":"10","key":"3044_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., Fang, M. A., Louie, G., Majithia, V., Ng, B., Bigham, R., Pianin, M., Shah, A. A., Sullivan, N., Turgunbaev, M., \u2026 Caplan, L. (2019). 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 71(10), 1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)"},{"issue":"6","key":"3044_CR19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., Balint, P. V., Bertheussen, H., Boehncke, W. H., Burmester, G. R., Canete, J. D., Damjanov, N. S., Kragstrup, T. W., Kvien, T. K., Landew\u00e9, R., \u2026 Smolen, J. S. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6), 700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Annals of the Rheumatic Diseases"},{"key":"3044_CR20","unstructured":"Simponi, Summary of Product Characteristics. Retrieved April 8, 2021, from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf"},{"issue":"3","key":"3044_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","volume":"39","author":"MV Hernandez","year":"2019","unstructured":"Hernandez, M. V., Sanchez-Piedra, C., Garcia-Magallon, B., Cuende, E., Manero, J., Campos-Fernandez, C., Martin-Domenech, R., Del Pino-Montes, J., Manrique, S., Castro-Villegas, M. C., Ruiz-Montesinos, D., Sanchez-Alonso, F., Diaz-Gonzalez, F., Cea-Calvo, L., G\u00f3mez-Reino, J. J., BIOBADASER Study. (2019). Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatology International, 39(3), 509\u2013515. https:\/\/doi.org\/10.1007\/s00296-018-4177-z","journal-title":"Rheumatology International"},{"issue":"5","key":"3044_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027456","volume":"9","author":"K Luttropp","year":"2019","unstructured":"Luttropp, K., Dozier, M., Justo, N., Cornillie, F., Kachroo, S., Govoni, M., Salomonsson, S., Black, C. M., & Khalifa, A. (2019). Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: A systematic literature review. British Medical Journal Open, 9(5), e027456. https:\/\/doi.org\/10.1136\/bmjopen-2018-027456","journal-title":"British Medical Journal Open"},{"issue":"5","key":"3044_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics, 4(5), 353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"PharmacoEconomics"},{"key":"3044_CR24","unstructured":"Reilly Associates. WPAI Translation. Retrieved April 8, 2021, http:\/\/www.reillyassociates.net\/WPAI_Translations.html."},{"key":"3044_CR25","unstructured":"EuroQol Research Foundation. EQ-5D-5L, About. Retrieved April 8, 2021, from https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/."},{"issue":"1","key":"3044_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward, L. C., Spoorenberg, A., Cook, S. A., Whalley, D., Helliwell, P. S., Kay, L. J., McKenna, S. P., Tennant, A., van der Heijde, D., & Chamberlain, M. A. (2003). Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases, 62(1), 20\u201326. https:\/\/doi.org\/10.1136\/ard.62.1.20","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"3044_CR27","first-page":"119","volume":"19","author":"JE Graham","year":"2015","unstructured":"Graham, J. E., Rouse, M., Twiss, J., McKenna, S. P., & Vidalis, A. A. (2015). Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Hippokratia, 19(2), 119\u2013124.","journal-title":"Hippokratia"},{"issue":"2","key":"3044_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/ard.2003.006296","volume":"63","author":"SP McKenna","year":"2004","unstructured":"McKenna, S. P., Doward, L. C., Whalley, D., Tennant, A., Emery, P., & Veale, D. J. (2004). Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis. Annals of the Rheumatic Diseases, 63(2), 162\u2013169. https:\/\/doi.org\/10.1136\/ard.2003.006296","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"3044_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.22365\/jpsych.2017.283.219","volume":"28","author":"\u0391 Heaney","year":"2017","unstructured":"Heaney, \u0391, Stepanous, J., McKenna, S. P., Athanassiou, P., & Vidalis, A. A. (2017). Translation and validation of the greek Psoriatic Arthritis Quality of Life Scale. Psychiatriki, 28(3), 219\u2013225. https:\/\/doi.org\/10.22365\/jpsych.2017.283.219","journal-title":"Psychiatriki"},{"issue":"12","key":"3044_CR30","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology, 21(12), 2286\u20132291.","journal-title":"The Journal of Rheumatology"},{"issue":"4","key":"3044_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10198-016-0807-0","volume":"18","author":"JN Yfantopoulos","year":"2017","unstructured":"Yfantopoulos, J. N., & Chantzaras, A. E. (2017). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics\u202f: HEPAC\u202f: Health Economics in Prevention and Care, 18(4), 519\u2013531. https:\/\/doi.org\/10.1007\/s10198-016-0807-0","journal-title":"The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care"},{"key":"3044_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/528105","volume":"2014","author":"F Salaffi","year":"2014","unstructured":"Salaffi, F., Ciapetti, A., Carotti, M., Gasparini, S., & Gutierrez, M. (2014). Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world. BioMed Research International, 2014, 528105. https:\/\/doi.org\/10.1155\/2014\/528105","journal-title":"BioMed Research International"},{"issue":"1","key":"3044_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1996","unstructured":"van Gestel, A. M., Prevoo, M. L., van\u2019t Hof, M. A., van Rijswijk, M. H., van de Putte, L. B., & van Riel, P. L. (1996). Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis and Rheumatism, 39(1), 34\u201340. https:\/\/doi.org\/10.1002\/art.1780390105","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"3044_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000382","volume":"3","author":"RM Fleischmann","year":"2017","unstructured":"Fleischmann, R. M., van der Heijde, D., Gardiner, P. V., Szumski, A., Marshall, L., & Bananis, E. (2017). DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 3(1), e000382. https:\/\/doi.org\/10.1136\/rmdopen-2016-000382","journal-title":"RMD Open"},{"key":"3044_CR35","unstructured":"Kr\u00fcger, K., Remstedt, S., Thiele, A., & Klaudius, I. (2017). Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany [abstract]. Arthritis Rheumatol 69 (suppl 10). Retrieved March 4, 2018, from http:\/\/acrabstracts.org\/abstract\/golimumab-improves-work-productivity-and-activity-impairment-in-patients-with-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-and-psoriatic-arthritis-psa-interim-results-from-a-non-intervent\/."},{"issue":"6","key":"3044_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101499","volume":"33","author":"H Xu","year":"2019","unstructured":"Xu, H., & Yin, J. (2019). HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis Best practice & research. Clinical Rheumatology, 33(6), 101499. https:\/\/doi.org\/10.1016\/j.berh.2020.101499","journal-title":"Clinical Rheumatology"},{"issue":"2","key":"3044_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1128\/CMR.17.2.348-369.2004","volume":"17","author":"I Colmegna","year":"2004","unstructured":"Colmegna, I., Cuchacovich, R., & Espinoza, L. R. (2004). HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations. Clinical Microbiology Reviews, 17(2), 348\u2013369. https:\/\/doi.org\/10.1128\/CMR.17.2.348-369.2004","journal-title":"Clinical Microbiology Reviews"},{"key":"3044_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608134","volume":"11","author":"D Wakefield","year":"2021","unstructured":"Wakefield, D., Clarke, D., & McCluskey, P. (2021). Recent Developments in HLA B27 Anterior Uveitis. Frontiers in Immunology, 11, 608134. https:\/\/doi.org\/10.3389\/fimmu.2020.608134","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"3044_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/cer-2020-0092","volume":"9","author":"K Krueger","year":"2020","unstructured":"Krueger, K., Remstedt, S., Thiele, A., & Hohenberger, S. (2020). Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. Journal of Comparative Effectiveness Research, 9(12), 891\u2013902. https:\/\/doi.org\/10.2217\/cer-2020-0092","journal-title":"Journal of Comparative Effectiveness Research"},{"issue":"6","key":"3044_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/1756-185X.13526","volume":"22","author":"P Claudepierre","year":"2019","unstructured":"Claudepierre, P., Van den Bosch, F., Sarzi-Puttini, P., Vastesaeger, N., Govoni, M., & Kachroo, S. (2019). Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. International Journal of Rheumatic Diseases, 22(6), 995\u20131001. https:\/\/doi.org\/10.1111\/1756-185X.13526","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"598","key":"3044_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/annrheumdis-2018-eular.2411","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco, C., Mueller, T., Zamani, O., Kurtz, U., Egger, S., Resch-Passini, J., Totzauer, A., Eisterer, W., Yazdani-Biuki, B., Schwingenschloegl, T., Peichl, P., Kraus, A., Naerr, G. W., & Rickert, V. (2018). FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AxSPA): interim results from a non-interventional study in Austria (Go Active). Annals of Rheumatic Diseases, 77(598), 2\u2013599. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.2411","journal-title":"Annals of Rheumatic Diseases"},{"key":"3044_CR42","unstructured":"Szende, A., Janssen, B., & Cabas\u00e9s, J. (2014). Self-Reported Population Health: An International Perspective Based on EQ-5D. Springer Dordrecht Heidelberg New York, London. 2014. Springer Open. Retrieved September 17, 2020 from https:\/\/eq-5dpublications.euroqol.org\/download?id=0_54006&fileId=54415."},{"issue":"7","key":"3044_CR43","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1524-4733.2008.00356.x","volume":"11","author":"N Kontodimopoulos","year":"2008","unstructured":"Kontodimopoulos, N., Pappa, E., Niakas, D., Yfantopoulos, J., Dimitrakaki, C., & Tountas, Y. (2008). Validity of the EuroQoL (EQ-5D) instrument in a Greek general population. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 11(7), 1162\u20131169. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00356.x","journal-title":"Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"issue":"12","key":"3044_CR44","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s10067-020-05171-8","volume":"39","author":"P Sidiropoulos","year":"2020","unstructured":"Sidiropoulos, P., Bounas, A., Athanassiou, P., Koutsianas, C., Petrikkou, E., Kaltsonoudis, E., Drosos, A., & Vassilopoulos, D. (2020). Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Clinical Rheumatology, 39(12), 3643\u20133652. https:\/\/doi.org\/10.1007\/s10067-020-05171-8","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"3044_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone, F., Santo, L., Anelli, M. G., Bucci, R., Semeraro, A., Quarta, L., D\u2019Onofrio, F., Marsico, A., Carlino, G., Casilli, O., Cacciapaglia, F., Zuccaro, C., Falappone, P. C., Cantatore, F. P., Muratore, M., & Lapadula, G. (2017). Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 47(1), 108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"3044_CR46","first-page":"804","volume":"35","author":"M Manara","year":"2017","unstructured":"Manara, M., Caporali, R., Favalli, E. G., Grosso, V., Atzeni, F., Sarzi Puttini, P., Gorla, R., Bazzani, C., Fusaro, E., Pellerito, R., Rocchetta, P. A., & Sinigaglia, L. (2017). Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry. Clinical and Experimental Rheumatology, 35(5), 804\u2013809.","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"2","key":"3044_CR47","first-page":"254","volume":"36","author":"K Thomas","year":"2018","unstructured":"Thomas, K., Flouri, I., Repa, A., Fragiadaki, K., Sfikakis, P. P., Koutsianas, C., Kaltsonoudis, E., Voulgari, P. V., Drosos, A. A., Petrikkou, E., Sidiropoulos, P., & Vassilopoulos, D. (2018). High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Real world data from 328 patients. Clinical and Experimental Rheumatology, 36(2), 254\u2013262.","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"10","key":"3044_CR48","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W. P., Scott, B. B., Boice, J. A., Berd, Y., Bergman, G., Curtis, S., Tzontcheva, A., Huyck, S., & Weng, H. H. (2015). A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 67(10), 2702\u20132712. https:\/\/doi.org\/10.1002\/art.39257","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)"},{"issue":"2","key":"3044_CR49","first-page":"199","volume":"37","author":"F Van den Bosch","year":"2019","unstructured":"Van den Bosch, F., Flipo, R. M., Braun, J., Vastesaeger, N., Kachroo, S., & Govoni, M. (2019). Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: The QUO-VADIS study. Clinical and Experimental Rheumatology, 37(2), 199\u2013207.","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"10","key":"3044_CR50","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3899\/jrheum.180718","volume":"46","author":"JD Reveille","year":"2019","unstructured":"Reveille, J. D., Deodhar, A., Caldron, P. H., Dudek, A., Harrison, D. D., Kim, L., Lo, K. H., Leu, J. H., & Hsia, E. C. (2019). Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study. The Journal of Rheumatology, 46(10), 1277\u20131283. https:\/\/doi.org\/10.3899\/jrheum.180718","journal-title":"The Journal of Rheumatology"},{"issue":"10","key":"3044_CR51","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh, A., McInnes, I. B., Krueger, G. G., Gladman, D., Beutler, A., Gathany, T., Mack, M., Tandon, N., Han, C., & Mease, P. (2013). Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care & Research, 65(10), 1666\u20131673. https:\/\/doi.org\/10.1002\/acr.22044","journal-title":"Arthritis Care & Research"},{"issue":"6","key":"3044_CR52","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde, D., Deodhar, A., Braun, J., Mack, M., Hsu, B., Gathany, T. A., Inman, R. D., Han, C., & GO-RAISE investigators,. (2014). The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. The Journal of Rheumatology, 41(6), 1095\u20131103. https:\/\/doi.org\/10.3899\/jrheum.131003","journal-title":"The Journal of Rheumatology"},{"issue":"1","key":"3044_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12891-017-1711-1","volume":"18","author":"JC Huang","year":"2017","unstructured":"Huang, J. C., Qian, B. P., Qiu, Y., Wang, B., Yu, Y., Zhu, Z. Z., Hu, J., & Qu, Z. (2017). Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: A retrospective case series study. BMC Musculoskeletal Disorders, 18(1), 352. https:\/\/doi.org\/10.1186\/s12891-017-1711-1","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"4","key":"3044_CR54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11136-010-9771-9","volume":"20","author":"H Bodur","year":"2011","unstructured":"Bodur, H., Ataman, S., Rezvani, A., Bu\u011fdayc\u0131, D. S., Cevik, R., Birtane, M., Ak\u0131nc\u0131, A., Altay, Z., G\u00fcnayd\u0131n, R., Yener, M., Ko\u00e7yi\u011fit, H., Duru\u00f6z, T., Yazgan, P., Cakar, E., Ayd\u0131n, G., Hepg\u00fcler, S., Altan, L., K\u0131rnap, M., Olmez, N., \u2026 G\u00fcnendi, Z. (2011). Quality of life and related variables in patients with ankylosing spondylitis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 20(4), 543\u2013549. https:\/\/doi.org\/10.1007\/s11136-010-9771-9","journal-title":"Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"issue":"1","key":"3044_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3899\/jrheum.160411","volume":"45","author":"LE Dean","year":"2018","unstructured":"Dean, L. E., Macfarlane, G. J., & Jones, G. T. (2018). Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the scotland registry for ankylosing spondylitis. The Journal of Rheumatology, 45(1), 62\u201369. https:\/\/doi.org\/10.3899\/jrheum.160411","journal-title":"The Journal of Rheumatology"},{"issue":"4","key":"3044_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","volume":"23","author":"P Machado","year":"2011","unstructured":"Machado, P., & van der Heijde, D. (2011). How to measure disease activity in axial spondyloarthritis? Current Opinion in Rheumatology, 23(4), 339\u2013345. https:\/\/doi.org\/10.1097\/BOR.0b013e3283470f23","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"3044_CR57","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/ard.2009.117945","volume":"69","author":"VP Nell-Duxneuner","year":"2010","unstructured":"Nell-Duxneuner, V. P., Stamm, T. A., Machold, K. P., Pflugbeil, S., Aletaha, D., & Smolen, J. S. (2010). Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Annals of the Rheumatic Diseases, 69(3), 546\u2013549. https:\/\/doi.org\/10.1136\/ard.2009.117945","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"3044_CR58","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels, M. M., Aletaha, D., Alasti, F., & Smolen, J. S. (2016). Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Annals of the Rheumatic Diseases, 75(5), 811\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"3044_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","volume":"6","author":"LJ Tucker","year":"2019","unstructured":"Tucker, L. J., Coates, L. C., & Helliwell, P. S. (2019). Assessing disease activity in psoriatic arthritis: A literature review. Rheumatology and Therapy, 6(1), 23\u201332. https:\/\/doi.org\/10.1007\/s40744-018-0132-4","journal-title":"Rheumatology and Therapy"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-03044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-021-03044-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-03044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:20:40Z","timestamp":1650540040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-021-03044-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,28]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s11136-021-03044-4","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,28]]},"assertion":[{"value":"18 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Giorgios Vosvotekas has received honoraria from Abbvie, MSD, Novartis, Pfizer, Genesis, and Roche. Dr Gkikas Katsifis has received honoraria from Abbvie, Aenorasis, Amgen, Bausch Health, BMS, Celgene, Janssen, MSD, Novartis, Roche, Pfizer, and UCB. Dr Maria G. Tektonidou has received honoraria from Abbvie, Genesis, GSK, MSD, Novartis, Pfizer, and UCB. Dr Evangelia Petrikkou and Dr Achilleas Livieratos are employees of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. For the remaining authors none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed and conducted in accordance with the guidelines for Good Pharmacoepidemiology Practice of the International Society for Pharmacoepidemiology, the ethical principles laid down in the Declaration of Helsinki, and all applicable local rules and regulations. The study was approved by the competent Institutional Review Boards (IRBs) of all participating hospital sites. Participation of private practice investigators was approved by the Institutional Review Board of a participating hospital located in the same geographic region as the Private Practice. Specifically, the institutional ethics committees (Institutional Review Boards) that reviewed and approved the study, and corresponding ethical review reference numbers include IRB of 251 Air Force General Hospital (reference number: 862\/03-Mar-2017), IRB of Iaso General Clinic (reference number: 79\/05-Apr-2017), IRB of \u201cAg. Pavlos\u201d General Hospital of Thessaloniki (reference number: 19\/16-Feb-2017), IRB of \u201cOlympion\u201d Rehabilitation Center of Patras, IRB of University General Hospital of Ioannina (reference number: 13\/19-Jun-2019), IRB of \u201cIppokrateio\u201d General Hospital of Thessaloniki (reference number: 248\/19-Jun-2017), IRB of \u201cKAT\u201d Hospital (reference number: 266\/01-Aug-2017), IRB of \u201cAg. Andreas\u201d General Hospital of Patras (reference number: 11\/10-Mar-2017), IRB of \u201cG. Gennimatas\u201d General Hospital of Athens (reference number: 7856\/07-Mar-2017), IRB of Private Practice under University General Hospital of Heraklion (reference number: 1261\/08-Mar-2017), IRB of Naval Hospital of Athens (reference number: 2\/1721-Feb-2017), IRB of University General Hospital of Larissa (reference number: 4829\/17-Mar-2017), IRB of University General Hospital of Heraklion (reference number: 1261\/08-Mar-2017), IRB of \u201cLaiko\u201d General Hospital (reference number: 386\/06-Apr-2017), IRB of \u201cIppokrateio\u201d General Hospital of Athens (reference number: 7396\/18-May-2017), Private Practice under IRB of Iaso General Clinic (reference number: 278\/08-Nov-2017), Private Practice under IRB of Euromedica Clinic Thessaloniki (reference number: 520\/17-Mar-2017), Private Practice under IRB of \u201cAg. Pavlos\u201d of Thessaloniki (reference number: 19\/16-Feb-2017), and IRB of Private Practice under University General Hospital of Heraklion (reference number: 1261\/08-Mar-2017).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All persons gave their informed consent prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided consent for publication of the material collected in the context of this study in a non-identifiable manner.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}